WaveMan
WaveMan · Company
GRCE · Grace Therapeutics, Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

GRCE Grace Therapeutics (GRCE) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Pharmaceutical preparations · CIK 0001444192
Quote by TradingView
C-suite buying · 1
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
22
13F, latest reported quarter

What the filings say about GRCE

Insiders, 180 days
+$774.5K net bought
2 buyers

Grace Therapeutics insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, Grace Therapeutics, Inc. insiders bought a net $774.5K of stock across 19 Form 4 purchases and sales, with 2 insiders buying. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
Opaleye Management Inc.
BUY
2026-10-26 SEC
66,411
$117.4K
n/a
Context
  • 17 earlier Form 4 trades (code P or S) here by this insider (17 buys), the last on Oct 22, 2026.
  • The trade is 2.2% of the 3,036,411 shares held after it.
  • No other insider bought within 30 days.
  • 22 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider Opaleye Management Inc. bought about $117.4K of GRCE on Oct 26, 2026; 22 funds added in the latest 13F quarter.
Opaleye Management Inc.
BUY
2026-10-26 SECtraded 2026-10-22
21,390
$41.2K
n/a
Context
  • 16 earlier Form 4 trades (code P or S) here by this insider (16 buys), the last on Oct 19, 2026.
  • The trade is 0.7% of the 2,970,000 shares held after it.
  • No other insider bought within 30 days.
  • 22 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider Opaleye Management Inc. bought about $41.2K of GRCE on Oct 22, 2026; 22 funds added in the latest 13F quarter.
Opaleye Management Inc.
BUY
2026-10-21 SECtraded 2026-10-19
4,256
$8.0K
-5.7%
Context
  • 15 earlier Form 4 trades (code P or S) here by this insider (15 buys), the last on Oct 16, 2026.
  • The trade is 0.1% of the 2,948,610 shares held after it.
  • No other insider bought within 30 days.
  • 22 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider Opaleye Management Inc. bought about $8.0K of GRCE on Oct 19, 2026; 22 funds added in the latest 13F quarter.
Opaleye Management Inc.
BUY
2026-10-16 SEC
36,347
$68.8K
-3.7%
Context
  • 14 earlier Form 4 trades (code P or S) here by this insider (14 buys), the last on Oct 15, 2026.
  • The trade is 1.2% of the 2,944,354 shares held after it.
  • No other insider bought within 30 days.
  • 22 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider Opaleye Management Inc. bought about $68.8K of GRCE on Oct 16, 2026; 22 funds added in the latest 13F quarter.
Opaleye Management Inc.
BUY
2026-10-16 SECtraded 2026-10-15
23,485
$45.7K
-3.7%
Context
  • 13 earlier Form 4 trades (code P or S) here by this insider (13 buys), the last on Oct 14, 2026.
  • The trade is 0.8% of the 2,908,007 shares held after it.
  • No other insider bought within 30 days.
  • 22 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider Opaleye Management Inc. bought about $45.7K of GRCE on Oct 15, 2026; 22 funds added in the latest 13F quarter.
19 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 14 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net +$774.5K over 180 days
+$774.5K over 90 days · +$560.5K of it by a 10%+ holder
more than 86% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
22 funds bought in last quarter
below 67% of Pharma & Biotech
Revenue
+50920.4% year over year
the highest in Pharma & Biotech
Margin
-7.8% net margin
more than 66% of Pharma & Biotech
Buybacks
no share repurchases reported
Short interest
12.6% of the float short (float per yahoo 2026-10-27) · 15.5 days to cover · settled 2026-10-15
more than 65% of Pharma & Biotech
What changed in the last 30 days
Oct 26Insider Opaleye Management Inc. bought $504.4K (15 trades, Sep 21 to Oct 26)

Watch GRCE

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-42.5%12M
-43%-7%+28%+63%2025-102025-122026-022026-042026-062026-082026-10 2026-09-09 · Kohli Prashant bought $214.0K2026-10-26 · Opaleye Management Inc. bought $117.4K2026-10-01 · Opaleye Management Inc. bought $79.0K2026-10-16 · Opaleye Management Inc. bought $68.8K2026-10-15 · Opaleye Management Inc. bought $45.7K2026-10-02 · Opaleye Management Inc. bought $41.4K2026-10-22 · Opaleye Management Inc. bought $41.2K2026-08-14 · Opaleye Management Inc. bought $24.2K2026-10-14 · Opaleye Management Inc. bought $21.7K2026-09-21 · Opaleye Management Inc. bought $20.5K2026-09-08 · Opaleye Management Inc. bought $19.7K2026-09-29 · Opaleye Management Inc. bought $16.4K2026-10-12 · Opaleye Management Inc. bought $14.6K2026-09-09 · Opaleye Management Inc. bought $12.2K2026-09-23 · Opaleye Management Inc. bought $11.2K2026-10-09 · Opaleye Management Inc. bought $10.9K2026-10-19 · Opaleye Management Inc. bought $8.0K2026-10-08 · Opaleye Management Inc. bought $4.2K2026-10-05 · Opaleye Management Inc. bought $3.5K
Insider buy
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns GRCE: institutional holders (13F)

13F holdings, latest reported quarter
Cerity Partners LLC
849,055 sh
$1.9M
Eversept Partners, LP
772,900 sh
$1.8M
BANK OF AMERICA CORP /DE/
494,698 sh
$1.1M
VANGUARD CAPITAL MANAGEMENT LLC
411,714 sh
$934.6K
CITADEL ADVISORS LLC
349,740 sh
$793.9K

Congress trades in GRCE

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

GRCE planned insider sales (Form 144)

No planned-sale notices
No insider has filed to sell. Watch this after a run-up.

GRCE mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
iShares Micro-Cap ETF
$79.9K position · as of 2026-06-30
0.0%
TIFF MULTI-ASSET FUND
$36.9K position · as of 2026-06-30
0.0%
1290 VT Micro Cap Portfolio
$5.3K position · as of 2026-06-30
0.0%
Total Stock Market Index Trust
$1.8K position · as of 2026-06-30
0.0%
Fidelity Nasdaq Composite Index Fund
$14.3K position · as of 2026-05-31
0.0%
VANGUARD BALANCED INDEX FUND
$25.8K position · as of 2026-06-30
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Clinical pipeline
4 registered trials, 1 still running (ClinicalTrials.gov). A status change is dated here weeks before the press release.
3
Phase 1
0 active
1
Phase 3
1 active
Matched by sponsor name. Trials run under a subsidiary's own name are not included.
Executive pay vs shareholder return
CEO pay, headline and as actually paid, against the company's return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2022
$1.1M
$1.3M
$467.2K
-90%
n/a
2021
$1.5M
$2.0M
$915.0K
-75%
n/a
Tagged by the company under SEC Item 402(v). Returns are cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders are net buyers of their own stock.
The record shows a net $774.5K bought by insiders over 180 days, 22 funds added last quarter. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

GRCE financials

Revenue growth
+50920.4%
XBRL, annual
Net margin
-7.8%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
n/a
fewer than four consecutive quarters of revenue filed
Net margin, TTM
n/a
needs four consecutive quarters of both revenue and net income
Free cash flow, TTM
n/a
capex not filed for the four quarters
Debt to equity
n/a
no debt line filed
Cash flow to debt
n/a
no debt line filed
Return on equity
-36.2%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
-33.7%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
pre-tax loss, no effective tax rate to apply
Return on capital employed
-41.1%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
n/a
no debt line filed
FCF yield
n/a
capex not filed for the four quarters
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2026-032025-032024-032023-03
Operating income-$11.1M-$16.7M-$12.9M-$52.2M
Net income-$7.8M-$9.6M-$12.9M-$42.4M
EPS (diluted)-0.47-0.79-1.35-5.71
Operating cash flow-$8.9M-$14.9M-$12.3M-$15.9M
Cash$17.0M$22.1M$23.0M$27.9M
SEC XBRL, fiscal years, as known on 2026-10-28

GRCE Stock Sonar score 5/7 axes

Find similar shapesCompare

GRCE ranks highest on growth (99th percentile) and insider conviction (83rd), and lowest on institutional and government (33rd), among Pharma & Biotech peers.

ProfitGrowthInsidersInstitutionsRisk
Profitability
59
Inputs
  • Return on equity-36.2% · 63 pct, sector of 545
  • Return on assets-33.7% · 57 pct, sector of 691
  • Return on invested capitalpre-tax loss, no effective tax rate to apply
  • Return on capital employed-41.1% · 58 pct, sector of 576
Growth
100
Inputs
  • Revenue growth, YoY+50920% · 100 pct, sector of 505
  • Backlog growth, YoYno backlog line filed, or no year-earlier backlog
Insider conviction
83
Inputs
  • Net Form 4 buying (codes P and S), 180d$774K · 86 pct, sector of 428
  • Insider buyers, 180d2 · 81 pct, sector of 437
Institutional and government
33
Inputs
  • Funds adding, latest quarter22 · 33 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
34
Inputs
  • Short interest, % of float+12.9% · 31 pct, sector of 813
  • Recalls per $1B revenue, 3ynot measured for this sector, almost no peer has an event
  • EPA cases per $1B revenue, 5ynot measured for this sector, almost no peer has an event
  • New text in Risk Factors, latest 10-K+13.2% · 36 pct, sector of 511
2 not measured: Financial health, US patents
  • Financial health needs 1 of 2 inputs, 0 present: no debt line filed
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

GRCE filings, in plain words

Are Grace Therapeutics insiders buying or selling GRCE?

In the 180 days to 2026-10-28, Grace Therapeutics insiders were net buyers, a net $774.5K across purchases and sales reported on Form 4, by 2 buyers.

Read the full summary

In the 180 days to 2026-10-28, Grace Therapeutics insiders were net buyers of GRCE, a net $774.5K across purchases and sales reported on Form 4 by 2 buyers. Most of that figure, $560.5K, came from a holder of 10% or more rather than an officer or director. 2 different insiders reported purchases within the last 90 days, a cluster buy, which is rarer than a single purchase. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies